NewslettersCell Therapy News Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T Cell Immunotherapy against Cancer By Danielle Corrigan - August 8, 2022 0 Researchers combined CAR T19 with the FDA-approved BCL-2-inhibitor, venetoclax, and demonstrated in vivo synergy in venetoclax-sensitive non-Hodgkin lymphoma. [Cancer Discovery] Abstract